Reata Pharmaceuticals Inc - Ordinary Shares - Class A

-12.56 (-7.64%)
Other Pre-Announcement

Reata Pharmaceuticals Inc Announces Third Quarter 2020 Financial Results

Published: 11/09/2020 12:01 GMT
Reata Pharmaceuticals Inc (RETA) - Reata Pharmaceuticals, Inc. Announces Third Quarter 2020 Financial Results and Provides an Update on Business Operations and Clinical Development Programs.
Q3 Non-GAAP Loss per Share $1.31.
Q3 GAAP Loss per Share $1.94.
Q3 Earnings per Share Estimate $-1.98 -- Refinitiv Ibes Data (analyst estimates).
Reported Long Term Efficacy Data From Eagle (open-label Extension) Study.
Reported Positive Baseline-controlled Study Data From Moxie Extension Study Provided to FDA.
Barcona Study Enrollment Ongoing.
Reata Pharma -positive Year 2 Data From Pivotal Cardinal Study of Bardoxolone Methyl in Patients With Chronic Kidney Disease Caused by Alport Syndrome.
Bardoxolone Treatment Was Generally Reported to Be Well-tolerated.
Expects Existing Cash and Cash Equivalents Will Be Sufficient to Enable It to Fund Operations Through End of 2023.
Reata Pharma -for Phase 3 Cardinal Study of Bardoxolone, Co Plans to Proceed With Submission of an NDA for Full Marketing Approval in U.S. in Q1 2021.
Reata Pharma- for Phase 3 Cardinal Study of Bardoxolone for Alport Syndrome , Co to Continue Preparations to File for Marketing Approval in Europe.